Your browser doesn't support javascript.
loading
Construction and validation of chemoresistance-associated tumor- infiltrating exhausted-like CD8+ T cell signature in breast cancer: cr-TILCD8TSig.
Cai, D Q; Cai, Diankui; Zou, Yiping; Chen, Xumeng; Jian, Zhixiang; Shi, Mude; Lin, Ye; Chen, Jueming.
Afiliación
  • Cai DQ; Department of General Surgery, Sun Yat-Sen Memorial Hospital, Guangzhou, China.
  • Cai D; Department of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong Province, China.
  • Zou Y; Department of General Surgery, Sun Yat-Sen Memorial Hospital, Guangzhou, China.
  • Chen X; Department of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong Province, China.
  • Jian Z; Department of Pharmacology, School of Pharmaceutical Sciences, Hunan University of Chinese Medicine, Changsha, China.
  • Shi M; Department of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong Province, China.
  • Lin Y; Guangdong ACXEL Micro & Nano Tech Co., Ltd, Foshan, China.
  • Chen J; Department of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong Province, China.
Front Immunol ; 14: 1120886, 2023.
Article en En | MEDLINE | ID: mdl-36949939
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Front Immunol Año: 2023 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Front Immunol Año: 2023 Tipo del documento: Article País de afiliación: China